Morphgesic Sr (Morphine Sulfate)

Morphine sulfate works by binding to µ‑opioid receptors in the brain and spinal cord. This binding activates inhibitory pathways that reduce the transmission of pain signals and produce sedation, resulting in effective analgesia.

The appropriate dose of Morphgesic Sr is individualized by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, age, renal and hepatic function, and other clinical factors. No fixed regimen is provided here.

Safety of morphine sulfate during pregnancy and lactation is not well established. Clinicians must weigh potential benefits against possible risks to the fetus or infant, and use the medication only if clearly needed.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Morphgesic Sr delivers morphine sulfate, a prototypical µ‑opioid agonist with a well‑characterized efficacy and safety profile. Compared with newer synthetic opioids, it has a longer history of clinical use, predictable pharmacokinetics, and is generally less expensive, though it shares similar risk categories for respiratory depression and dependence.

Store Morphgesic Sr at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure it is out of reach of children and unauthorized persons.

Morphgesic Sr is formulated for oral administration. The tablet (or oral solution, if supplied) should be taken whole with water, unless otherwise directed by a healthcare professional. Swallowing whole helps maintain consistent absorption.

The most serious risks include respiratory depression, severe hypotension, and the potential for dependence or addiction with prolonged use. These events require immediate medical attention and careful monitoring, especially in opioid‑naïve patients or when combined with other depressant drugs.

Morphgesic Sr should be avoided in patients with known hypersensitivity to morphine or other opioids, in those with severe respiratory insufficiency, acute or severe asthma, and in individuals taking monoamine oxidase inhibitors within 14 days. Caution is also advised for patients with significant hepatic or renal impairment.